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administered dose. A reduction in the ratio DOPAC/OHTyr from placebo to the highest dose was 
observed, compatible with a shift in the dopamine metabolism to preferently produce OHTyr instead of 
DOPAC. Also a dose-dependent increase in plasma ethanol concentrations and subjective effects was 
observed. This study demonstrates an endogenous production of OHTyr and Tyr in relation to ethanol 
administered dose in humans. Biological effects of both phenols from this source should be 
investigated in future studies. 
 
 
 
 
1 
 
TITLE 1 
Ethanol induces hydroxytyrosol formation in humans 2 
 3 
Authors 4 
Clara Pérez-Mañáa,b*, Magí Farréa,b*, Mitona Pujadasa,c, Cristina Mustataa,  5 
Esther Menoyoa, Antoni Pastora,b,c, Klaus  Langohra,d , Rafael de la Torrea,c,e 6 
  7 
aHuman Pharmacology and Clinical Neurosciences Research Group, 8 
Neurosciences Research Program, IMIM (Hospital del Mar Medical Research 9 
Institute), Barcelona, Spain  10 
bDepartment of Pharmacology, Therapeutics and Toxicology, Autonomous 11 
University of Barcelona, Barcelona, Spain  12 
cCIBER de Fisiopatología Obesidad y Nutrición, Santiago de Compostela, 13 
Spain  14 
dDepartment of Statistics and Operations Research, Universitat Politècnica de 15 
Cataluña/BARCELONATECH, Barcelona, Spain 16 
ePompeu Fabra University (CEXS-UPF), Barcelona, Spain   17 
*Authorship credit should be equally distributed among the authors 18 
independently of the order. 19 
Corresponding autor: 20 
Name: Rafael de la Torre, DPharm, PhD 21 
e-mail: rtorre@imim.es 22 
address: Doctor Aiguader 88, 08003 Barcelona 23 
tel:  +34 933160484  fax: +34 933160467 24 
  25 
*Manuscript
Click here to view linked References
2 
 
 Abstract 26 
Previous studies in animals have shown an increase of hydroxytyrosol             27 
(OHTyr), a potent phenolic antioxidant and a minor metabolite of dopamine 28 
(also called 3,4-dihydroxyphenylethanol or DOPET), after ethanol intake. The 29 
interaction between ethanol and dopamine metabolism is the probable 30 
mechanism involved. The aim of the study was to establish the contribution of 31 
the dose of ethanol on OHTyr formation. 24 healthy male volunteers were 32 
included. Subjects were distributed in three different cohorts and each 33 
volunteer received two doses of ethanol or placebo. Doses of ethanol 34 
administered were 6, 12, 18, 24, 30 and 42g. Study design was double-blind, 35 
randomized, crossover and controlled. Hydroxytyrosol, tyrosol (Tyr), 3,4-36 
dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) urinary 37 
excretion, ethanol plasma concentrations and drunkenness were evaluated 38 
along a 6-hour period. Urinary excretion of OHTyr and Tyr increased with 39 
ethanol administered dose. A reduction in the ratio DOPAC/OHTyr from 40 
placebo to the highest dose was observed, compatible with a shift in the 41 
dopamine metabolism to preferently produce OHTyr instead of DOPAC. Also a 42 
dose-dependent increase in plasma ethanol concentrations and subjective 43 
effects was observed. This study demonstrates an endogenous production of 44 
OHTyr and Tyr in relation to ethanol administered dose in humans. Biological 45 
effects of both phenols from this source should be investigated in future 46 
studies. 47 
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Abbreviations 51 
4-HPAA        4-hydroxyphenylacetic acid 52 
AE                adverse events 53 
AUC0-6h_c      area under the blood concentration curve from 0 to 6h  54 
AUC0-6h_e         area under the curve for effects (drunkenness) from 0 to 6h  55 
Cmax                     maximum blood alcohol concentration 56 
DA                dopamine 57 
DOPAC 3,4-dihydroxyphenylacetic acid 58 
DOPAL  3,4-dihydroxyphenylacetaldehyde  59 
DOPET 3,4-dihydroxyphenylethanol 60 
EIA   enzyme immunoassay  61 
Emax                    maximum alcohol effect (drunkenness) 62 
GCMS           gas chromatography mass spectrometry 63 
HDL              high density lipoprotein 64 
HVA            homovanillic acid 65 
HPLC/MS/MS liquid chromatography coupled to tandem mass spectrometry  66 
LDL               low density lipoprotein 67 
OHTyr  hydroxytyrosol 68 
tmax_c                  time to reach maximum blood alcohol concentration 69 
tmax_e                  time to reach maximum effect (drunkenness) 70 
Tyr  tyrosol  71 
VAS              visual analog scale 72 
  73 
 74 
 75 
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1. Introduction 76 
Accumulating scientific evidence indicates that light to moderate drinking done 77 
on a daily basis may significantly reduce the risks of coronary heart disease 78 
(CHD) and all-cause mortality [1-3]. A J-shaped relationship describes the 79 
association between alcohol and total mortality. Ethanol doses higher than 4 80 
drinks per day in men or 2 drinks per day in women are associated with 81 
increased risk of medical complications and death [1].  82 
Moderate alcohol consumption is thought to be protective because improves 83 
insulin sensitivity, reduces several coagulation factors and inflammation, 84 
increases fibrinolytic capacity and also rises high density lipoprotein (HDL) 85 
cholesterol concentrations in a dose dependent manner [4,5]. However, 86 
mechanisms involved are poorly understood and controversy still exists 87 
regarding if beneficial effects are primarily attributable to ethanol [6,7], to 88 
polyphenols or to both components in some alcoholic beverages, like wine [8].  89 
Hydroxytyrosol (OHTyr) is the main phenol present in olive oil and also in minor 90 
quantities in wine [9]. It is one of the most potent antioxidants present in the 91 
Mediterranean Diet. In the EUROLIVE study, oxidative stress markers including 92 
oxidized low-density lipoprotein levels, decreased linearly with the increasing 93 
phenolic content (including OHTyr) of olive oil [10]. According to these data a 94 
health claim was released by the European Food Safety Authority (EFSA) for 95 
the consumption of 5 mg per day of OHTyr and its derivatives in olive oil [11] as 96 
protective of LDL particles from oxidative damage. In terms of safety it has been 97 
shown in vitro that OHTyr is non-genotoxic and non-mutagenic at 98 
concentrations exceeding those attainable after intake [12]. 99 
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Data from a bioavailability study of resveratrol after red wine administration in 100 
healthy volunteers showed a recovery of substantial amounts of OHTyr that 101 
could not be explained by the small quantities contained in wine. A 200% of the 102 
administered dose was recovered in urine suggesting OHTyr endogenous 103 
formation after wine intake [9]. 104 
Furthermore, in a subsample (n=1009) of a large intervention clinical trial, 105 
intended at demonstrating the effects of a Mediterranean-style Diet on primary 106 
prevention of cardiovascular disease, it was observed that baseline OHTyr 107 
urinary concentrations correlated with wine consumption , but also with ethanol 108 
ingestion [13]. 109 
Previous studies in animals have shown an increase of DOPET (3,4-110 
dihydroxyphenylethanol, OHTyr) formation, a minor metabolite of dopamine 111 
(DA), due to the presence of ethanol [14,15].  In a study with liver slices the 112 
addition of ethanol changed the ratio DOPAC (3,4-dihydroxyphenylacetic 113 
acid)/OHTyr from 10 to 0.25, compatible with a shift in DA metabolism from the 114 
oxidative pathway to produce DOPAC to the reductive one to produce OHTyr 115 
[16]. Other routes for OHTyr production had also been described in animals 116 
through the conversion of DOPAC to OHTyr via DOPAC reductase [17] or 117 
through DOPAL oxidation via an aldehyde reductase (ADR) [18]. MOPET (4-118 
hydroxy-3-methoxyphenylethanol or HVAL) is the methylated metabolite of 119 
OHTyr while homovanillic acid (HVA) is the main metabolite of DOPAC. While 120 
OHTyr and HVAL are present physiologically in low concentrations in biological 121 
matrices DOPAC and HVA are more abundant and the last one is a typical 122 
biomarker of dopamine turnover. See in Figure 1 a general description of all 123 
components involved in dopamine metabolism.  124 
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On the other hand, ethanol is converted to acetaldehyde by hepatic oxidative 125 
metabolism in a reaction regulated by alcohol dehydrogenase (ADH). In turn 126 
acetaldehyde is converted in acetic acid (acetate) by acetaldehyde 127 
dehydrogenase (ALDH). Both reactions produce reduced nicotinamide adenine 128 
dinucleotide (NADH). The reductive environment created is thought to be 129 
responsible for the change in the aldehyde (DOPAL) metabolism enhancing the 130 
formation of the alcohol derivative (OHTyr or DOPET) instead of the acid one 131 
(DOPAC) [16]. A similar shift was also observed for serotonin, where the 132 
alcohol metabolite 5-hydroxytryptophol was preferably produced after ethanol 133 
intake instead of 5-hydroxyindolacetic acid [19]. 134 
Taking into account the studies with ethanol conducted in animals and 135 
preliminary data obtained with wine in humans it was hypothesized that the 136 
interaction of ethanol (also present in wine) with the metabolism of DA to 137 
produce OHTyr, could explain, at least in part, the human beneficial health 138 
effects of low doses of ethanol [9]. 139 
Tyrosol (Tyr or 2-(4-hydroxyphenyl)ethanol) is also a well-known phenolic 140 
compound that is mainly present in extra-virgin olive oil and wine. It has also 141 
anti-inflammatory and antioxidant properties [20,21].  However, in comparison 142 
with OHTyr, Tyr has lower antioxidant activity because it lacks of the hydroxyl 143 
group in position 3 of the phenolic ring [22]. In animals Tyr excretion increased 144 
after ethanol administration due to an alteration of tyramine metabolism [23].  In 145 
our study Tyr excretion was measured as a secondary outcome.  146 
The aim of the study was to establish the contribution of the dose of ethanol on 147 
OHTyr formation. 148 
 149 
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2. Materials and methods 150 
2.1 Participants 151 
The study was conducted in accordance with the Declaration of Helsinki and 152 
approved by the local Ethics Committee (CEIC Parc de Salut Mar). Informed 153 
consent was obtained from all volunteers previously to any study related 154 
procedure and they were paid for their participation. The study was registered in 155 
clinicaltrials.gov (NCT01788670). 156 
Eligibility criteria required social ethanol consumption. Subjects with daily 157 
alcohol consumption higher than 30g or meeting criteria of ethanol abuse or 158 
dependence were excluded. To confirm health status, volunteers were 159 
interviewed by a physician and underwent a general physical examination, 160 
routine laboratory tests, urinalysis, and a 12-lead electrocardiogram. 161 
2.2 Study design, procedures and outcomes 162 
The study design was double-blind, randomized, crossover, and controlled with 163 
placebo. Participants were distributed in three different cohorts. In cohort 1, 164 
doses of 18 and 30g of ethanol were administered to 12 subjects. In cohort 2, 165 
doses of 6 and 12g of ethanol were administered to 6 subjects. Finally in cohort 166 
3 doses of 24 and 42g of ethanol were administered to 6 subjects. Thus each 167 
participant received two doses of ethanol and placebo in three different 168 
experimental sessions (6h duration per session) with a minimum wash out 169 
period of three days between them. Participants were randomly assigned to 170 
each treatment sequence using a balanced 3 x 3 Latin square design.  171 
Subjects were requested to abstain from ethanol ingestion three days before 172 
each session. Olive oil and olives were also prohibited due to its high OHTyr 173 
content. Beverages containing xanthines were not allowed in the previous 24 h 174 
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and during the experimental sessions. Subjects were also requested to abstain 175 
for any drug of abuse during the study. Breath alcohol tests and drug of abuse 176 
tests in urine (Instant-View®, Alpha Scientific Designs, Inc, Poway, CA, USA) 177 
were conducted along the study to confirm abstinence.   178 
On session day, participants arrived at the clinical trials unit at 08:00 AM. An 179 
intravenous catheter was inserted into a subcutaneous vein to obtain blood 180 
samples. Treatments were administered at 8:30 AM in fasting conditions and a 181 
light meal (half of a cheese sandwich) was provided 2 and 6h after treatment 182 
administration. Additional water was given to volunteers at 2h (300 ml) and 4h 183 
(100ml) after administration in order to assure urine generation in each time 184 
interval. Participants left the unit 6 hours after administration once verified that 185 
the breath alcohol test was negative. Tobacco smoking was prohibited during 186 
the experimental sessions. 187 
The main outcome of the study was total OHTyr urinary concentrations from 0 188 
to 6h after administration. Secondary outcomes included ethanol plasma 189 
concentrations and subjective effects (drunkenness feelings). DOPAC, HVA 190 
and total tyrosol (Tyr) urinary concentrations from 0 to 6 h after administration 191 
were also assessed. Total OHTyr was calculated as the sum of: OHTyr-3-O-192 
glucuronide, OHTyr-4-O-glucuronide, OHTyr-3-O-sulfate, free OHTyr and total 193 
4-hydroxy-3-methoxyphenylethanol (HVAL). Total HVAL in turn was the sum of 194 
free HVAL + HVAL-4-O-glucuronide.  Total Tyr in urine was calculated as the 195 
sum of free Tyr and Tyr-4-O-glucuronide. 196 
Ethanol in plasma was determined at pre-dose and at 15, 30, 45 minutes, and 197 
1, 1.5, 2, 3, 4, 6 hours after administration. Subjective effects were measured by 198 
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means of a visual analogue scale (VAS) of drunkenness from 0 to 100 mm at 199 
pre-dose and 30 minutes and at 1, 2, 4 and 6h after administration [24]. 200 
Urine samples were collected just before administration (spot sample) and at 201 
different interval periods after treatment administration (0-2h, 2-4h, 4-6h). Urine 202 
0-6h was the sum of the three collection intervals.  203 
Heart rate, blood pressure and oral temperature were measured with 204 
CarescapeTM V100 monitor (GE Healthcare. Milwaukee, WI) across the 205 
sessions (baseline, and at 1 and 6h after administration) and adverse events 206 
during the study were also recorded. 207 
2.3 Treatments 208 
Ethanol conditions were obtained mixing ethanol (pharmaceutical grade) and 209 
lemon flavored water (Fontvella, Barcelona, Spain). Placebo consisted in lemon 210 
flavored water. The total volume of the beverages ingested was 150 ml. 211 
Beverages were administered in opaque recipients, served cold and ingested 212 
along 5 minutes. 213 
2.4 Samples preparation and analysis 214 
Blood samples were collected in lithium heparin tubes for alcohol analysis. After 215 
centrifugation at 3000 rpm for 10 minutes at 4° C, plasma was transferred to 216 
tubes sealed with a plastic paraffin film and frozen immediately to avoid alcohol 217 
evaporation. Blood ethanol concentrations were determined with the DRI® Ethyl 218 
Alcohol Assay (Thermo Fisher, Fremont, CA, USA). 219 
Urine samples were collected in different containers and the total amount of 220 
urine generated in each time interval was registered. Three aliquots were saved 221 
from each time interval for the assessment of phenolic compounds and DA 222 
metabolites’ concentrations. Urines were treated with hydrochloric acid to 223 
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acidify the sample. Phenolic compounds and its metabolites were determined 224 
by liquid chromatography coupled to tandem mass spectrometry 225 
(HPLC/MS/MS), as previously described [25,26]. DOPAC and HVA were 226 
measured by GCMS [27,28]. 227 
2.5 Statistical analysis   228 
Differences from baseline were calculated for both subjective and physiological 229 
outcomes. Regarding plasma concentrations of ethanol and subjective effects 230 
the following pharmacokinetic parameters were calculated: maximum 231 
concentration (Cmax), or maximum effect (Emax), the time to reach the maximum 232 
concentration (tmax_c) or effect (tmax_e), and area under the curve from 0 to 6 233 
hours for concentrations (AUC0-6h_c) and effects (AUC0-6h_e). The AUC were 234 
calculated using the trapezoidal rule. The same parameters were calculated for 235 
physiological outcomes. Total urinary excretion of OHTyr and Tyr as well as the 236 
ratio between DOPAC and OHTyr excretion were calculated from 0 to 6h. For 237 
each of the outcomes of interest, a linear mixed model with a random intercept 238 
and ethanol dose as independent variable was fitted. These models account for 239 
the correlation between the repeated measures within study participants. In the 240 
case of phenols’ excretion, DOPAC/OHTyr ratio, and the AUC0-6h of the ethanol 241 
concentrations, the relationship between the outcomes and ethanol dose was 242 
not always linear. For that reason, log-transformations of only the outcomes and 243 
of both the outcomes and the ethanol dose were also considered and those 244 
models that showed the most adequate model fit based on graphical inspection 245 
of the corresponding residual plots were used for the corresponding analysis. In 246 
addition, the analyses for the main outcomes were also performed with the 247 
weight-adjusted ethanol dose as independent variable. Pearson’s correlation 248 
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coefficient was used to quantify the association between ethanol 249 
concentrations, subjective effects, total OHTyr, total Tyr and DOPAC excretion 250 
(0-6h). Statistical significance was set at 0.05 and the statistical software 251 
package R, version 3.1.1 (R Foundation for Statistical Computing, Vienna, 252 
Austria) was used for the analyses. 253 
 254 
3. Results 255 
3.1 Participants 256 
Twenty four male healthy volunteers were included in the study. All were non-257 
smokers but eight (27.8%). Their average consumption of alcohol was 7g a day 258 
(5 units per week; 1 unit=10g of ethanol). The mean age, body weight and body 259 
mass index were 25.8 ± 4.5 years, 79.2 ± 6.5kg and of 24.3 ± 2.2kg/m2, 260 
respectively.  261 
3.2 Ethanol concentrations 262 
Baseline samples were all negative for ethanol. Ethanol pharmacokinetic 263 
parameters calculated from 0 to 6h after administration increased with the 264 
ethanol administered dose. Cmax increased in a dose linear manner (each gram 265 
of ethanol increased the Cmax on average in 0.43 nmol/ml (95%-CI: [0.4, 0.5]; 266 
p<0.001). The logarithm of the AUC0-6h_c increased linearly as a function of the 267 
logarithm of the ethanol dose (log-dose): on average, augmenting the log-dose 268 
by one unit, the log-AUC0-6h_c  increased by 1.47 units per gram of alcohol 269 
(95%-CI: [1.3, 1.7]; p<0.001), which is equivalent to an increase of the AUC0-6h_c 270 
by factor 1.47. Maximum blood alcohol concentrations were reached at 23 271 
minutes (6g), 30 minutes (12g, 18g), 37 minutes (30g) and 45 minutes (24g, 272 
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42g) after administration. Model-based mean estimations of the Cmax and AUC0-273 
6h_c and the corresponding 95% prediction intervals are shown in Table 1.  274 
 275 
Ethanol could be detected longer for higher doses. Some correlative doses (24-276 
30g and 12-18g) showed similar concentrations probably because they were 277 
obtained in different subjects (see Figure 2).  278 
3.3 Phenols and DA metabolites excretion 279 
Baseline OHTyr concentrations were low and not different between treatment 280 
conditions (n=24: 0.4 ± 0.5 nmol/ml). 281 
OHTyr total urinary excretion from 0 to 6h increased with ethanol dose (each 282 
gram of ethanol increased the log-OHTyr on average in 0.026 units (95%-CI: 283 
[0.02, 0.04]; p<0.001), which is equivalent to an increase by factor 1.03 per 284 
gram of alcohol). High variability was found between subjects as the coefficient 285 
of variation of the different doses ranged from 49% to 78%. A clear dose 286 
relationship was found when high and low dose of ethanol given to the same 287 
subjects were compared (18 vs. 30g or 24 vs. 42g). However excretion with 24g 288 
was higher than with 30g probably due to intersubject variability. Observed 289 
values of total OHTyr excretion and its metabolites are presented in Figures 2 290 
and 3. 291 
Model-based mean estimations for total OHTyr and the corresponding 95% 292 
prediction intervals are shown in Table 2.  293 
OHTyr was excreted mainly in its conjugated form with sulfate (Figure 4). The 294 
sulfate metabolite and HVAL increased with ethanol administered dose while 295 
this relationship was not found with glucuronides. Amounts of free OHTyr 296 
excreted were very low and apparently unrelated to ethanol dose. 297 
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Baseline tyrosol concentrations were also not different among conditions (n=24: 298 
0.1 ± 0.1 nmol/ml). Total Tyr excretion also increased with ethanol dose (each 299 
gram of ethanol increased the log-Tyr on average in 0.051 units (95%-CI:[0.04, 300 
0.07]; p<0.001), which is equivalent to an increase by factor 1.05 per gram of 301 
ethanol). See Table 2 for model-based estimations of the mean. 302 
DOPAC and HVA excretion did not show any statistically significant relationship 303 
with ethanol administered dose (p=0.286 and p=0.498). DOPAC excretion 304 
mean values for 0, 6, 12, 18, 24, 30 and 42g of ethanol were 3239, 3484, 4688, 305 
2024, 2559, 2190, 3393 nmol, respectively. HVA excretion for all doses was 306 
higher than DOPAC excretion (1.6-3.7 times). 307 
A statistically significant association was observed between both ethanol Cmax 308 
and AUC0-6h_c with the logarithm of total OHTyr excretion (r= 0.53; p=0.005 and 309 
r=0.45; p=0.02, respectively).  DOPAC/OHTyr ratio decreased with the ethanol 310 
content of the beverage (p<0.001). The ratios observed were 14.0 ± 14.7 (0g), 311 
10.1 ± 5.6 (6g), 11.7 ± 8.7 (12g), 3.9 ± 2.6 (18g), 3.8 ± 2.8 (24g), 4.0 ± 2.5 (30g) 312 
and 3.6 ± 2.0 (42g) and estimated values ranged from 8.4 (95% CI: 6.0-12.0) for 313 
placebo to 2.4 (95% CI:1.5-3.7) with the highest dose. 314 
3.4 Subjective effects 315 
Drunkenness increased with ethanol dose (except for doses of 12-18g, obtained 316 
in different subjects). High variability in subjective effects was found between 317 
subjects as coefficient of variation of different doses ranged from 63% to 150%. 318 
The median tmax_e value was 30 minutes for all ethanol containing beverages 319 
except 1 hour for the dose of 42g. Subjective effects time-curves are presented 320 
in Figure 5.  321 
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The highest drunkenness-Emax (38 of 100) and AUC0-6h_e (96 mm x h) were 322 
obtained with the highest dose of ethanol. AUC0-6h_e and Cmax showed a slight 323 
correlation (r=0.35; p=0.01) similar to the correlation between Emax and Cmax 324 
(r=0.31, p=0.055). 325 
3. 5 Physiological outcomes and adverse events 326 
No differences were found in heart rate, blood pressure and temperature 327 
between the different doses of ethanol administered. 328 
No serious adverse events (AE) were reported during the study. 14 subjects 329 
reported a total of 26 AE. Those considered to be related with treatment (13) 330 
were mainly headaches (9). One subject reported nausea, unsteadiness and 331 
dizziness with 42g of ethanol.  332 
3. 6 Alcohol dose adjusted to weight 333 
No overlap between doses was observed when the dose of ethanol was 334 
adjusted to weight (6g: 79 ± 4 mg/kg, 12g: 157 ± 7 mg/kg, 18g: 226 ± 23 mg/kg, 335 
24g: 305 ± 25 mg/kg, 30g: 376 ± 38 mg/kg, 42g: 533 ± 43 mg/kg). Results 336 
obtained with ethanol adjusted doses for the different outcomes showed the 337 
same trends previously described (data not shown). 338 
 339 
4. Discussion 340 
In this study we report for the first time in healthy volunteers and in a controlled 341 
setting the endogenous generation of OHTyr after the ingestion of ethanol. 342 
OHTyr formation was ethanol dose dependent. Doses tested (except 42g) are 343 
in the range of daily doses associated with a reduction of all-cause mortality [1] 344 
and recent consensus recommendations about moderate alcohol use [29]. 345 
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As previously mentioned, in animal studies it has been shown that ethanol can 346 
induce a shift in the metabolism of DA from a predominantly oxidative to a 347 
reductive pathway with formation of OHTyr (DOPET) instead of DOPAC [14, 16] 348 
In our study a reduction in the ratio DOPAC/OHTyr from placebo to 42g of 349 
ethanol was observed (from 14 to 3.6), compatible with the occurrence of a shift 350 
in the oxidative metabolism of DA with ethanol. OHTyr excretion with 42g of 351 
ethanol triplicated the values obtained with placebo (1296 vs 427 nmol). 352 
However OHTyr excretion was at least 3 times lower (for the dose of 24g) in 353 
comparison with the administration of the same amount of ethanol contained in 354 
wine in a previous study [9].  Therefore the endogenous generation of OHTyr 355 
via ethanol interaction with DA oxidative metabolism only explains a relatively 356 
small portion of the recoveries of OHTyr after wine ingestion for the same 357 
alcohol dose.   358 
To explain biological activities when free forms of phenols are almost 359 
undetectable it has been postulated that conjugates could act as depot forms 360 
and be hydrolyzed intracellularly releasing free OHTyr [30,31].  361 
The demonstration in humans that ethanol ingestion can endogenously produce 362 
a potent phenolic antioxidant is in contrast with the fact that ethanol is typically 363 
considered a pro-oxidant substance [32].  In a previous observational study a 364 
relationship between circulating levels of oxidized LDL and ethanol consumption 365 
was reported [33]. Future experiments should evaluate whether the antioxidant 366 
effects of OHTyr generated in vivo can be overshadowed by the pro-oxidant 367 
influence of ethanol. The balance between wine phenolic compounds and 368 
ethanol concentrations has been already suggested may be critical in the 369 
protection of LDL oxidation [34]. In addition to the OHTyr ability of protecting 370 
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LDL against oxidation it also displays anti-inflammatory and antiaggregant 371 
activities [8,35] that could be also contributing in ethanol cardioprotective 372 
effects.  373 
The increase in Tyr excretion with ethanol dose is reported for the first time in 374 
humans. Its formation is also ethanol dose dependent. Amounts recovered are 375 
about 40% of those observed for OHTyr at the higher ethanol doses.  The 376 
mechanism involved could be a shift in tyramine oxidative metabolism to 377 
preferably produce Tyr instead of 4-hydroxyphenylacetic acid (4-HPAA), also 378 
described in animals [23]. Globally Tyr recovery increased 10 fold in the range 379 
of doses tested.   380 
No relationship was found between DOPAC or HVA excretion and ethanol 381 
administered dose. As these compounds are found in very high concentrations 382 
in body fluids in comparison with OHTyr, it is plausible that small changes due 383 
to OHTyr formation could be not detected. 384 
Ethanol concentrations and time to reach maximum concentration increased 385 
with the administered dose. Furthermore a linear relationship was described for 386 
Cmax while for AUC0-6h_c the linearity was lost at higher doses. Delayed tmax can 387 
be explained due to a reduction in gastric emptying with more concentrated 388 
beverages and AUC0-6h_c disproportionate increase was related to the limited 389 
capacity of alcohol elimination by ADH [36,37]. 390 
Drunkenness feelings reported were mild and increased with ethanol 391 
administered dose. High interindividual variability was found probably due to 392 
different degrees of tolerance to ethanol. No serious adverse events were 393 
reported although headaches that appeared after several hours of consumption 394 
with higher doses could correspond to hangover symptomatology.  395 
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The study has several strengths and limitations. The cross over design allowed 396 
the same subjects to be treated with at least two different doses of ethanol and 397 
the double blind procedure was optimal to study ethanol subjective effects. 398 
However, for practical issues not all subjects received all doses and some 399 
comparisons were indirect. We enrolled only male volunteers for avoiding 400 
potential sex differences in ethanol pharmacokinetics and subjective effects, 401 
mainly due to a lower volume of distribution and a reduced tolerance to ethanol 402 
in women [38,39]. The ethanol dose was not adjusted to weight however no 403 
overlap between doses was observed when doses were adjusted. The 404 
biological implications of the observations made still has to be investigated, 405 
most probably with one of the ethanol doses tested but with additional 406 
comparison groups other than placebo.  407 
 408 
5. Conclusions 409 
There is a dose-related increase of urinary excretion of OHTyr and Tyr after 410 
ethanol administration. Results can be explained by endogenous generation 411 
produced by shifts in dopamine and tyramine oxidative metabolism, 412 
respectively, in the presence of ethanol. The biological significance of these 413 
findings deserves further evaluation in future clinical trials.  414 
 415 
 416 
6. Registration 417 
The trial was registered in Clinicaltrials.gov (NCT01788670). 418 
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Table 1. Model-based estimations of the mean (95% prediction intervals) of the 592 
pharmacokinetic parameters as a function of ethanol dose (from 0 to 42g). 593 
Parameter 6g 12g 18g 24g 30g 42g 
AUC0-6h_c 
nmol x  h/ml 
2.5 
(1.8- 
3.4) 
6.8 
(4.4-
10.5) 
12.3 
(7.4-
20.6) 
18.9 
(10.8-
33.0) 
26.2 
(14.4-
47.7) 
43.0 
(22.2-
83.1) 
Cmax 
nmol/ml 
2.8 
(1.3-
4.3) 
5.4 
(4.2-
6.6) 
7.9 
(7.0-
8.9) 
10.5 
(9.6-
11.4) 
13.0 
(12.0-
14.0) 
18.1 
(16.5-
19.8) 
AUC0-6h_e 
mm x h 
-3.1 
(-18.1-
12.0) 
9.3 
(-3.7-
22.2) 
21.6 
(9.8-
33.4) 
33.9 
(22.1-
45.8) 
46.3 
(33.3-
59.3) 
58.6 
(43.6-
73.6) 
Emax 
mm 
1.3 
(-4.9-
7.4) 
7.1 
(1.7-
12.5) 
12.9 
(7.9-
17.9) 
18.8 
(14.0-
23.8) 
24.6 
(19.2-
30.0) 
30.5 
(24.3-
36.6) 
AUC0-6h_c, area under the blood concentration curve from 0 to 6h;  AUC0-6h_e,  594 
area under the curve for effects (drunkenness) from 0 to 6h;  Cmax, maximum 595 
blood alcohol concentration; Emax, maximum alcohol effect (drunkenness) 596 
 597 
 598 
 599 
 600 
 601 
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Table 2. Total OHTyr and Tyr urinary excretion from 0 to 6h after administration. 602 
Model-based estimations of the mean (95% prediction intervals) as a function of 603 
ethanol dose (from 0 to 42g). 604 
Urinary 
excretion 
0g 6g 12g 18g 24g 30g 42g 
Total OHTyr 
nmol 
322 
(235- 
441) 
375 
(281-
500) 
437 
(333-
574) 
510 
(389-
668) 
594 
(448-
788) 
693 
(509- 
942) 
941 
(640-
1385) 
Total Tyr 
nmol 
56 
(39-81) 
76 
(56-
103) 
103 
(79-
134) 
139 
(108-
180) 
189 
(142-
252) 
256 
(181-
362) 
470 
(282-
782) 
OHTyr, hydroxytyrosol; Tyr,tyrosol 605 
Figure 1. General diagram of dopamine metabolism. ADH: alcohol dehydrogenase.; ALDH: aldehyde
dehydrogenase; COMT:catechol-O-methyl transferase; DOPA: 3,4-dihydroxyphenylalanine; DOPAL: 3,4-
dihydroxyphenylacetaldehyde; DOPAC: 3,4-dihydroxyphenylacetic acid; DOPET: 3,4-dihydroxyphenylethanol;
HVA: homovanillic acid; HVAL: homovanillyl alcohol; MAO: monoaminooxidase; MOPAL: 3-methoxy-4-
hydroxyphenylacetaldehyde; MOPET: 4-hydroxy-3-methoxyphenylethanol.
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Figure 2. Plasma ethanol concentrations. Doses of 6 and 12g (n=6), doses of 18
and 30g (n=12), doses of 24 and 42g (n=6) and placebo (n=24).
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Figure 3. Urinary excretion of total hydroxytyrosol (OHTyr) and tyrosol (Tyr).  
Doses of 6 and 12g (n=4), doses of 18 and 30g (n=9), doses of 24 and 42g 
(n=6) and placebo (n=19).
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Figure 4. Urinary excretion of hydroxytyrosol (OHTyr) metabolites. Doses of 6 and 12g (n=4),
doses of 18 and 30g (n=9), doses of 24 and 42g (n=6) and placebo (n=19).Urinary excretion
of hydroxytyrosol metabolites.
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Figure 5. Ethanol-induced drunkenness. Doses of 6 and 12g (n=6), doses of 18
and 30g (n=12), doses of 24 and 42g (n=6) and placebo (n=24).
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Graphical abstract. Hydroxytyrosol generation due to the interaction of ethanol with dopamine metabolism.
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